Why RedHill Biopharma Stock Jumped on Tuesday
Shares of RedHill Biopharma (NASDAQ: RDHL) are on the move after Cantor Fitzgerald initiated coverage of the biopharmaceutical company. Investors excited about the buy rating have pushed the stock 20.3% higher as of 3:15 p.m. EDT on Tuesday.
RedHill Biopharma has three drugs on the market and six in clinical trials right now. With so much under the hood, it's no wonder analysts think it's a bargain at its ultralow valuation. Yesterday this company had a market cap of around $360 million.
Image source: Getty Images.
Source Fool.com
